# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 12, "Diabetologia", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasJournal> \"Diabetologia\"."
1, PublicationYear, 15, 19, "2015", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasPublicationYear> \"2015\"."
22, Title, 111, 246, "Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial .", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasTitle> \"Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment : a randomised clinical trial .\"."
2, Vildagliptin, 125, 137, "vildagliptin", "", 
9, Sitagliptin, 142, 153, "sitagliptin", "", 
16, Type2Diabetes, 171, 186, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
93450, DisorderOrSyndrome, 198, 214, "renal impairment", "", "<http://ctro/data#DisorderOrSyndrome_68369> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#DisorderOrSyndrome>. <http://ctro/data#ClinicalTrial_68299> <http://ctro/data#analysesHealthCondition> <http://ctro/data#DisorderOrSyndrome_68369>."
19, Randomized, 219, 229, "randomised", "", 
23, Author, 247, 255, "Kothny W", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasAuthor> \"Kothny W\"."
24, Author, 264, 277, "Lukashevich V", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasAuthor> \"Lukashevich V\"."
25, Author, 280, 288, "Foley JE", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasAuthor> \"Foley JE\"."
26, Author, 291, 301, "Rendell MS", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasAuthor> \"Rendell MS\"."
27, Author, 304, 315, "Schweizer A", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasAuthor> \"Schweizer A\"."
28, Switzerland, 397, 408, "Switzerland", "", 
31, ObjectiveDescription, 560, 697, "We compared the safety and efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment ( RI ) .", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#hasObjectiveDescription> \"We compared the safety and efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment ( RI ) .\"."
3, Vildagliptin, 599, 611, "vildagliptin", "", 
10, Sitagliptin, 616, 627, "sitagliptin", "", 
29, Precondition, 631, 695, "patients with type 2 diabetes and severe renal impairment ( RI )", "", "<http://ctro/data#Population_68315> <http://ctro/data#hasPrecondition> \"patients with type 2 diabetes and severe renal impairment ( RI )\"."
17, Type2Diabetes, 645, 660, "type 2 diabetes", "", 
93449, DisorderOrSyndrome, 672, 688, "renal impairment", "", 
32, Parallel, 725, 739, "parallel - arm", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
20, Randomized, 742, 752, "randomised", "", 
33, Multicenter, 755, 766, "multicentre", "", 
34, DoubleBlind, 769, 783, "double - blind", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
35, Duration, 786, 793, "24 week", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#hasCTduration> \"24 week\"."
121, Multicenter, 813, 849, "87 centres across Brazil and the USA", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
36, Brazil, 831, 837, "Brazil", "", 
37, USA, 846, 849, "USA", "", 
93444, Precondition, 852, 986, "Patients with type 2 diabetes , either drug naive or treated with any glucose - lowering agents , who had inadequate glycaemic control", "", "<http://ctro/data#Population_68315> <http://ctro/data#hasPrecondition> \"Patients with type 2 diabetes , either drug naive or treated with any glucose - lowering agents , who had inadequate glycaemic control\"."
18, Type2Diabetes, 866, 881, "type 2 diabetes", "", 
38, HbA1c, 989, 994, "HbA1c", "", 
41, Percentage, 1010, 1011, "%", "", 
130, ConcentrationUnit, 1022, 1032, "mmol / mol", "", 
93448, Precondition, 1044, 1069, "estimated GFR < 30 ml min", "", "<http://ctro/data#Population_68315> <http://ctro/data#hasPrecondition> \"estimated GFR < 30 ml min\"."
43, BioAndMedicalUnit, 1063, 1069, "ml min", "", 
44, BioAndMedicalUnit, 1087, 1088, "m", "", 
21, Randomized, 1104, 1114, "randomised", "", 
4, Vildagliptin, 1164, 1176, "vildagliptin", "", "<http://ctro/data#Medication_68353> <http://ctro/data#hasDrug> <http://ctro/data#Vildagliptin>."
46, DoseValue, 1177, 1179, "50", "", "<http://ctro/data#Medication_68353> <http://ctro/data#hasDoseValue> \"50\"."
48, mg, 1180, 1182, "mg", "", "<http://ctro/data#Medication_68353> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
50, Frequency, 1183, 1193, "once daily", "", "<http://ctro/data#Intervention_68341> <http://ctro/data#hasFrequency> \"once daily\"."
11, Sitagliptin, 1197, 1208, "sitagliptin", "", "<http://ctro/data#Medication_68360> <http://ctro/data#hasDrug> <http://ctro/data#Sitagliptin>."
47, DoseValue, 1209, 1211, "25", "", "<http://ctro/data#Medication_68360> <http://ctro/data#hasDoseValue> \"25\"."
49, mg, 1212, 1214, "mg", "", "<http://ctro/data#Medication_68360> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
51, Frequency, 1215, 1225, "once daily", "", "<http://ctro/data#Intervention_68347> <http://ctro/data#hasFrequency> \"once daily\"."
40, HbA1c, 1438, 1443, "HbA1c", "", 
52, FastingPlasmaGlucose, 1448, 1470, "fasting plasma glucose", "", 
53, FastingPlasmaGlucose, 1473, 1476, "FPG", "", 
55, EndPointDescription, 1564, 1578, "adverse events", "", 
56, NumberPatientsCT, 1602, 1605, "148", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#hasNumberPatientsCT> \"148\"."
57, Randomized, 1620, 1630, "randomised", "", 
58, NumberPatientsArm, 1633, 1635, "83", "", "<http://ctro/data#Arm_68323> <http://ctro/data#hasNumberPatientsArm> \"83\"."
5, Vildagliptin, 1639, 1651, "vildagliptin", "", 
59, NumberPatientsArm, 1656, 1658, "65", "", "<http://ctro/data#Arm_68332> <http://ctro/data#hasNumberPatientsArm> \"65\"."
12, Sitagliptin, 1662, 1673, "sitagliptin", "", 
60, TimePoint, 1711, 1719, "24 weeks", "", "<http://ctro/data#Outcome_68383> <http://ctro/data#hasTimePoint> \"24 weeks\". <http://ctro/data#Outcome_68410> <http://ctro/data#hasTimePoint> \"24 weeks\"."
152, Mean, 1735, 1739, "mean", "", "<http://ctro/data#Mean_68380> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_68378> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_68380>."
39, HbA1c, 1750, 1755, "HbA1c", "", "<http://ctro/data#Endpoint_68378> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
62, Reduction, 1762, 1768, "0 . 54", "", "<http://ctro/data#Outcome_68383> <http://ctro/data#hasChangeValue> \"0 . 54\"."
67, Percentage, 1769, 1770, "%", "", "<http://ctro/data#Endpoint_68378> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
64, Reduction, 1773, 1778, "5 . 9", "", 
164, ConcentrationUnit, 1779, 1789, "mmol / mol", "", 
61, TimePoint, 1799, 1807, "baseline", "", 
73, BaseLineValue, 1811, 1817, "7 . 52", "", "<http://ctro/data#Outcome_68383> <http://ctro/data#hasBaselineValue> \"7 . 52\"."
77, Percentage, 1818, 1819, "%", "", 
76, BaseLineValue, 1822, 1824, "59", "", 
165, ConcentrationUnit, 1825, 1835, "mmol / mol", "", 
6, Vildagliptin, 1843, 1855, "vildagliptin", "", 
63, Reduction, 1862, 1868, "0 . 56", "", "<http://ctro/data#Outcome_68410> <http://ctro/data#hasChangeValue> \"0 . 56\"."
68, Percentage, 1869, 1870, "%", "", 
65, Reduction, 1873, 1878, "6 . 1", "", 
166, ConcentrationUnit, 1879, 1889, "mmol / mol", "", 
66, TimePoint, 1899, 1907, "baseline", "", 
74, BaseLineValue, 1911, 1917, "7 . 80", "", "<http://ctro/data#Outcome_68410> <http://ctro/data#hasBaselineValue> \"7 . 80\"."
78, Percentage, 1918, 1919, "%", "", 
75, BaseLineValue, 1922, 1924, "62", "", 
167, ConcentrationUnit, 1925, 1935, "mmol / mol", "", 
13, Sitagliptin, 1943, 1954, "sitagliptin", "", 
79, PvalueDiff, 1957, 1970, "p  =  0 . 874", "", "<http://ctro/data#DiffBetweenGroups_68437> <http://ctro/data#hasPvalueDiff> \"p  =  0 . 874\"."
54, FastingPlasmaGlucose, 1975, 1978, "FPG", "", "<http://ctro/data#Endpoint_68446> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
80, Reduction, 1992, 1998, "0 . 47", "", "<http://ctro/data#Outcome_68451> <http://ctro/data#hasChangeValue> \"0 . 47\"."
81, SdDevChangeValue, 2003, 2009, "0 . 37", "", "<http://ctro/data#Outcome_68451> <http://ctro/data#hasSdDevChangeValue> \"0 . 37\"."
83, Millimoles_per_litre, 2010, 2018, "mmol / l", "", "<http://ctro/data#Endpoint_68446> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
7, Vildagliptin, 2024, 2036, "vildagliptin", "", 
85, Increment, 2054, 2060, "0 . 16", "", "<http://ctro/data#Outcome_68478> <http://ctro/data#hasChangeValue> \"0 . 16\"."
82, SdDevChangeValue, 2065, 2071, "0 . 43", "", "<http://ctro/data#Outcome_68478> <http://ctro/data#hasSdDevChangeValue> \"0 . 43\"."
84, Millimoles_per_litre, 2072, 2080, "mmol / l", "", 
14, Sitagliptin, 2086, 2097, "sitagliptin", "", 
86, PvalueDiff, 2100, 2113, "p  =  0 . 185", "", "<http://ctro/data#DiffBetweenGroups_68505> <http://ctro/data#hasPvalueDiff> \"p  =  0 . 185\"."
94, ConclusionComment, 2224, 2414, "At their recommended doses for severe RI , vildagliptin ( 50 mg once daily ) compared with sitagliptin ( 25 mg once daily ) demonstrated similar efficacy and both drugs were well tolerated .", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#hasConclusionComment> \"At their recommended doses for severe RI , vildagliptin ( 50 mg once daily ) compared with sitagliptin ( 25 mg once daily ) demonstrated similar efficacy and both drugs were well tolerated .\"."
8, Vildagliptin, 2267, 2279, "vildagliptin", "", 
88, DoseValue, 2282, 2284, "50", "", 
90, mg, 2285, 2287, "mg", "", 
92, Frequency, 2288, 2298, "once daily", "", 
15, Sitagliptin, 2315, 2326, "sitagliptin", "", 
89, DoseValue, 2329, 2331, "25", "", 
91, mg, 2332, 2334, "mg", "", 
93, Frequency, 2335, 2345, "once daily", "", 
95, ConclusionComment, 2415, 2513, "This study provides further support for the use of DPP - 4 inhibitors in patients with severe RI .", "", "<http://ctro/data#ClinicalTrial_68299> <http://ctro/data#hasConclusionComment> \"This study provides further support for the use of DPP - 4 inhibitors in patients with severe RI .\"."
93451, PharmacySponsored, 2592, 2640, "This study was planned and conducted by Novartis", "", 
96, PMID, 2711, 2719, "26067186", "", "<http://ctro/data#Publication_68292> <http://ctro/data#hasPMID> \"26067186\"."
